Natera, Inc.
NTRA · NASDAQ Global Select · USD
320,39USD
+9,72 (+3,13 %)Stand 9. Nov., 21:00
Nachbörslich323,00+2,61 (+0,81 %)19:49 ET
Kennzahlen
- Eröffnung
- 311,08
- Vortag
- 310,67
- Tagesspanne
- 308,03 – 324,77
- 52 Wochen
- 181,00 – 437,41
- Volumen
- 2,78 Mio.
- Ø Volumen
- 1,58 Mio.
- Börsenwert
- 46,18 Mrd. $
- KGV
- -281,0
- Gewinn je Aktie (TTM)
- -1,14
- Dividendenrendite
- 0,0 %
- Beta
- 1,5
- Nächste Zahlen
- 25. Feb. 2027
Finanzen
| USD | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Umsatz | 2,31 Mrd. | 1,7 Mrd. | 1,08 Mrd. | 820,22 Mio. | 625,49 Mio. |
| Herstellungskosten | 810,63 Mio. | 673,75 Mio. | 589,83 Mio. | 456,26 Mio. | 318,42 Mio. |
| Bruttogewinn | 1,5 Mrd. | 1,02 Mrd. | 492,74 Mio. | 363,97 Mio. | 307,07 Mio. |
| Forschung und Entwicklung | 624,11 Mio. | 404,14 Mio. | 320,68 Mio. | 316,42 Mio. | 264,21 Mio. |
| Vertrieb und Verwaltung | 1,18 Mrd. | 841,31 Mio. | 618,31 Mio. | 588,59 Mio. | 511,03 Mio. |
| Operatives Ergebnis | −309,91 Mio. | −222,29 Mio. | −446,25 Mio. | −541,04 Mio. | −468,17 Mio. |
| EBITDA | −220,54 Mio. | −148,08 Mio. | −397,8 Mio. | −520,8 Mio. | −451,54 Mio. |
| Nettogewinn | −208,16 Mio. | −190,43 Mio. | −434,8 Mio. | −547,8 Mio. | −471,72 Mio. |
| Gewinn je Aktie (verwässert) | -1,52 | -1,53 | -3,78 | -5,57 | -5,21 |
Umsatz nach Segment
Produkte · FY 2025
- Product2,3 Mrd. $99,55 %+36,24 %
- Licensing and other10,29 Mio. $0,45 %−13,04 %
Anteil · ggü. Vorjahr (FY 2024)
Regionen · FY 2025
- United States2,26 Mrd. $98,19 %+36,59 %
- Europe, Middle East, India, and Africa24,48 Mio. $1,06 %
- Americas, excluding U.S.9,35 Mio. $0,41 %+41,30 %
- Asia Pacific and Other8,01 Mio. $0,35 %−7,48 %
Anteil · ggü. Vorjahr (FY 2024)
Bewertung
Letzte 12 Monate
- KGV
- -281,0
- Kurs-Umsatz-Verhältnis
- 15,9
- Kurs-Buchwert-Verhältnis
- 24,7
- PEG
- -4,1
- Bruttomarge
- 65,2 %
- Operative Marge
- −9,0 %
- Nettomarge
- −5,7 %
- Verschuldungsgrad
- 0,1
- EV/EBITDA
- -325,0
- Eigenkapitalrendite
- −9,2 %
- Kapitalrendite (ROIC)
- −8,5 %
- Free-Cashflow-Rendite
- 0,1 %
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Bruttomarge | 64,8 % | 60,3 % | 45,5 % | 44,4 % | 49,1 % |
| Operative Marge | −13,4 % | −13,1 % | −41,2 % | −66,0 % | −74,8 % |
| Nettomarge | −9,0 % | −11,2 % | −40,2 % | −66,8 % | −75,4 % |
| KGV | -150,7 | -103,5 | -16,6 | -7,2 | -17,9 |
| Kurs-Umsatz-Verhältnis | 13,6 | 11,6 | 6,7 | 4,8 | 13,5 |
| Kurs-Buchwert-Verhältnis | 18,3 | 16,5 | 9,4 | 5,6 | 12,9 |
| Verschuldungsgrad | 0,1 | 0,2 | 0,6 | 0,6 | 0,6 |
| Liquidität 3. Grades | 3,4 | 4,0 | 4,1 | 3,9 | 5,0 |
| Dividendenrendite | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Unternehmenswert | 30,46 Mrd. | 18,98 Mrd. | 7 Mrd. | 3,93 Mrd. | 8,77 Mrd. |
| EV/EBITDA | -138,1 | -128,2 | -17,6 | -7,6 | -19,4 |
| Eigenkapitalrendite | −12,2 % | −15,9 % | −56,8 % | −77,6 % | −72,2 % |
| Kapitalrendite (ROIC) | −11,1 % | −15,8 % | −36,4 % | −46,2 % | −43,6 % |
| Free-Cashflow-Rendite | 0,3 % | 0,4 % | −4,0 % | −12,1 % | −4,4 % |
Wachstum
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Umsatz | +35,9 % | +56,7 % | +32,0 % | +31,1 % | +60,0 % |
| Bruttogewinn | +46,2 % | +107,6 % | +35,4 % | +18,5 % | +63,9 % |
| Operatives Ergebnis | −39,4 % | +50,2 % | +17,5 % | −15,6 % | −116,5 % |
| Nettogewinn | −9,3 % | +56,2 % | +20,6 % | −16,1 % | −105,3 % |
| Gewinn je Aktie | +0,7 % | +59,5 % | +32,1 % | −6,9 % | −83,5 % |
| Freier Cashflow | +57,6 % | +124,2 % | +40,3 % | −27,4 % | −86,2 % |
| Dividende je Aktie | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
Analysten
Einstufungen · Buy
- 0Stark kaufen
- 25Kaufen
- 3Halten
- 0Verkaufen
- 0Stark verkaufen
Kursziel
393,16
Durchschnitt · +22,71 %
Schätzungen
| FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|
| Umsatz (Ø) | 2,91 Mrd. | 3,52 Mrd. | 4,26 Mrd. |
| Umsatz (Tief – Hoch) | 2,88 Mrd. – 3 Mrd. | 3,41 Mrd. – 3,71 Mrd. | 3,91 Mrd. – 4,75 Mrd. |
| Gewinn je Aktie (Ø) | -1,45 | -0,37 | 1,27 |
| Gewinn je Aktie (Tief – Hoch) | -1,87 – -0,75 | -0,81 – -0,04 | -0,63 – 5,08 |
| Analysten | 5 | 11 | 15 |
Letzte Änderungen
- Baird9. Nov. 2026Outperform
- Evercore ISI Group6. Nov. 2026Outperform
- JP Morgan6. Nov. 2026Overweight
- BTIG27. Okt. 2026Buy
- Canaccord Genuity19. Okt. 2026Buy
- JP Morgan14. Okt. 2026Overweight
- TD Cowen13. Okt. 2026Buy
- Morgan Stanley13. Okt. 2026Overweight
Quartalszahlen
Nächste Zahlen: 25. Feb. 2027| Nov. 2026 | Aug. 2026 | Mai 2026 | Feb. 2026 | Nov. 2025 | Aug. 2025 | Mai 2025 | Feb. 2025 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | -0,28 | -0,49 | -0,54 | -0,51 | -0,39 | -0,62 | -0,64 | -0,38 |
| Gewinn je Aktie · Tatsächlich | -0,42 | -0,47 | -0,56 | 0,35 | -0,64 | -0,74 | -0,50 | -0,41 |
| Abweichung | −49,45 % | +4,85 % | −3,28 % | +168,35 % | −65,94 % | −20,24 % | +21,93 % | −7,57 % |
| Umsatz · Tatsächlich | 793,98 Mio. | 752,75 Mio. | 696,64 Mio. | 665,5 Mio. | 592,18 Mio. | 546,6 Mio. | 501,83 Mio. | 476,06 Mio. |
Dividenden und Splits
Keine Dividenden gezahlt.
Aktiensplits
–
Eigentümer
Institutionen
Q2 2026 · 13F
- Anteil institutioneller Investoren
- 96,26 %
- Investoren mit 13F-Meldung
- 886
Größte Investoren
- JPMORGAN CHASE & CO8,98 %12,87 Mio.
- BLACKROCK, INC.7,62 %10,91 Mio.
- PRICE T ROWE ASSOCIATES INC /MD/6,30 %9,02 Mio.
- VANGUARD CAPITAL MANAGEMENT LLC4,35 %6,23 Mio.
- VANGUARD PORTFOLIO MANAGEMENT LLC4,04 %5,78 Mio.
- FMR LLC3,80 %5,45 Mio.
- WELLINGTON MANAGEMENT GROUP LLP2,82 %4,04 Mio.
- STATE STREET CORP2,58 %3,66 Mio.
Insider-Geschäfte
- Sheena Jonathan2. Nov. 2026 · director, other: CO-FOUNDERVerkauf3 Aktien · 388,20
- Sheena Jonathan2. Nov. 2026 · director, other: CO-FOUNDERVerkauf109 Aktien · 400,29
- Rabinowitz Matthew2. Nov. 2026 · director, officer: EXECUTIVE CHAIRMANVerkauf17 Aktien · 388,20
- Rabinowitz Matthew2. Nov. 2026 · director, officer: EXECUTIVE CHAIRMANVerkauf731 Aktien · 400,29
- RABINOWITZ DANIEL2. Nov. 2026 · officer: SEC. AND CHIEF LEGAL OFFICERVerkauf7 Aktien · 388,20
- RABINOWITZ DANIEL2. Nov. 2026 · officer: SEC. AND CHIEF LEGAL OFFICERVerkauf334 Aktien · 400,29
- Moshkevich Solomon2. Nov. 2026 · officer: PRESIDENT, CLINICALDIAGNOSTICSVerkauf9 Aktien · 388,20
- Moshkevich Solomon2. Nov. 2026 · officer: PRESIDENT, CLINICALDIAGNOSTICSVerkauf410 Aktien · 400,29
Vergleichbare Unternehmen
Über das Unternehmen
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.
Führung
- Steven Leonard ChapmanChief Executive Officer & Director
- Michael BrophyChief Financial Officer
- Matthew RabinowitzCo-Founder & Executive Chairman
- John FeskoPresident & Chief Business Officer
- Solomon MoshkevichPresident of Clinical Diagnostics
- Daniel RabinowitzSecretary & Chief Legal Officer
- CEO
- Steven Leonard Chapman
- Mitarbeitende
- 6.138
- Hauptsitz
- Austin, TX, US
- Sektor
- Healthcare
- Branche
- Medical - Diagnostics & Research
- Börsengang
- 1. Juli 2015
- Website
- natera.com
Nachrichten
- Zacks Investment Research · 9. Nov., 14:31Natera Q3 Earnings Call Highlights $6B Target & Raised 2026 Outlook
- Zacks Investment Research · 9. Nov., 9:51NTRA Q3 Loss Wider Than Expected, Revenues Beat, '26 Sales View Up
- Defense World · 9. Nov., 4:05Natera, Inc. $NTRA Stock Holdings Lessened by Candriam S.C.A.
- Defense World · 7. Nov., 6:07Natera (NASDAQ:NTRA) Insider Sells $1,401,003.63 in Stock
- Defense World · 7. Nov., 5:06Natera (NASDAQ:NTRA) Insider Sells $1,401,003.63 in Stock
- Defense World · 7. Nov., 5:04Natera (NASDAQ:NTRA) CEO Sells $1,565,251.80 in Stock
- Seeking Alpha · 7. Nov., 4:54Natera, Inc. (NTRA) Q3 2026 Earnings Call Transcript
- Benzinga · 6. Nov., 11:25Natera Stock Plummets After Mixed Q3 Financials
- MarketBeat · 6. Nov., 5:15What Natera (NTRA) Said on Its Q3 Earnings Call
- Seeking Alpha · 6. Nov., 3:15Allspring Growth Fund Q3 2026 Performers And Detractors
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.